


LEGACY PHARMACEUTICALS SWITZERLAND

Fill & Finishing Portfolio » Datasheet Specials




Lyophilization of intermediates and active pharmaceutical products

Our customers rely on and trust our knowledge of freeze-drying and come to us for support with the manufacture of intermediates and active pharmaceutical ingredients (APIs) because of our longstanding experience. We perform aseptic freeze-drying processes in special bulk containers, offering substantial advantages over open lyophilization, which is more commonly used. The lyophilized material is protected by the containers from environmental influences, allowing for sterile manufacturing of lyophilization products. This bulk-produced lyophilizate powder can then be aseptically filled in various size vials and bottles as needed.

Dose Form	Manufacturing Process	Maximum Capacity (annually)
	Bulk freeze drying	Ice capacity 390 kg/batch and 18 m ² floor space

Aseptic powder filling in vials

Sterile powders can be introduced aseptically into modern powder filling equipment and poured into vials. Customer-specific docking systems are developed and implemented by our engineers. We have many years of experience in this area of manufacturing and are happy to provide this service to you.

Dose Form	Manufacturing Process	Maximum Capacity (annually)
	Aseptic powder filling in vials	Up to 30 million vials


LEGACY PHARMACEUTICALS SWITZERLAND

Fill & Finishing Portfolio » Datasheet Specials



Manufacturing of ophtalmic products

We manufacture aseptic eye gels in aluminium tubes. Like all other semi-solid formulations, these are also put in to the final packaging and made ready for shipment inline.

Dose Form	Manufacturing Process	Maximum Capacity (annually)
	Aseptic manufacturing and filling of tubes with eye gel	Up to 20 million tubes



Contact

Bastian Kloefler - Manager, Product Transfers
& Business Development Support

» bkloefler@legacypharm.com